Inventor

Christian Klein

Inventor

Bonstetten, CH

Overview

89→

Patents

1988–2020

Patent span

Chemistry

Primary field (CPC C)

Patents· 89 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides25%

A61KPreparations for medical, dental or toiletry purposes22%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%

C12NMicroorganisms or enzymes10%

G01NInvestigating or analysing materials by determining their chemical or physical properties8%

C07DHeterocyclic compounds3%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%

C07HSugars1%

PatentTitleYear

10,851,171Method for the selection of antibodies against BCMA2020 10,793,621Nucleic acid encoding dual Fc antigen binding proteins2020 10,781,262Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists2020 10,781,258Bispecific T cell activating antigen binding molecules2020 10,781,257Bispecific T cell activating antigen binding molecules2020 10,766,967Bispecific T cell activating antigen binding molecules2020 10,683,369Monoclonal antibodies against BCMA2020 10,683,345Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases2020 10,640,555Bispecific antigen binding proteins2020 10,633,451Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine2020 10,611,841Bispecific T cell activating antigen binding molecules2020 10,611,840Bispecific T cell activating antigen binding molecules2020 10,611,825Monovalent antigen binding proteins2020 10,603,360Combination IL-2 immunoconjugate therapy2020 10,596,257Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies2020 10,584,178Bispecific HER2 antibodies and methods of use2020 10,577,429Anti-FAP antibodies and methods of use2020 10,562,949Interleukin-2 fusion proteins and uses thereof2020 10,526,413Bispecific antibodies specific for OX402020 10,464,981Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules2019 10,392,445Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules2019 10,330,6693D ADCC NK FACS assay2019 10,323,099Multispecific domain exchanged common variable light chain antibodies2019 10,323,098Mutant interleukin-2 polypeptides2019 10,316,104Immunoconjugates2019 10,287,352Bispecific antibodies specific for PD1 and TIM32019 10,253,110Anti-FAP antibodies and methods of use2019 10,253,104Bispecific antibodies against CD3[?] and BCMA2019 10,202,464Immunoconjugates2019 10,184,009Mutant interleukin-2 polypeptides2019 10,155,815Bispecific T cell activating antigen binding molecules2018 10,138,293Bivalent, bispecific antibodies2018 10,106,600Bispecific antibodies2018 10,087,250Fc-free antibodies comprising two fab-fragments and methods of use2018 10,077,315Bispecific antibodies against CD3 and BCMA2018 9,982,036Dual FC antigen binding proteins2018 9,963,513Method for the selection of antibodies against BCMA2018 9,926,379'Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5'2018 9,926,567'Promoter'2018 9,914,776'Bispecific T cell activating antigen binding molecules'2018 9,890,204'Trivalent, bispecific antibodies'2018 9,708,396'Bispecific anti-VEGF/anti-ANG-2 antibodies'2017 9,695,233'Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases'2017 9,676,845'Bispecific antigen binding proteins'2017 9,650,442'Bispecific anti-EGFR/anti IGF-1R antibodies'2017 9,539,251'Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor'2017 9,526,797'Combination IL-2 immunoconjugate therapy'2016 9,447,159'Immunoconjugates'2016 9,415,090'VEGF-D/VEGFR2/3-mediated regulation of dendrites'2016 9,382,323'Multispecific antibodies comprising full length antibodies and single chain fab fragments'2016 9,340,609'Antibodies against human angiopoietin 2'2016 9,266,938'Mutant interleukin-2 polypeptides'2016 9,266,967'Bivalent, bispecific antibodies'2016 9,156,913'Anti-tenascin-C A2 antibodies and methods of use'2015 9,109,027'Antibodies against human angiopoietin 2'2015 9,080,183'Promoter'2015 9,073,986'Antibodies against human angiopoietin 2'2015 9,011,847'Anti-FAP antibodies and methods of use'2015 8,945,552'Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies'2015 8,796,424'Tri- or tetraspecific antibodies'2014 8,703,132'Bispecific, tetravalent antigen binding proteins'2014 8,703,130'Bispecific anti-VEGF/anti-ANG-2 antibodies'2014 8,399,626'Antibodies against human angiopoietin 2'2013 8,361,747'Antibodies against human angiopoietin 2'2013 8,268,314'Bispecific anti-VEGF/anti-ANG-2 antibodies'2012 8,242,247'Bivalent, bispecific antibodies'2012 8,227,577'Bivalent, bispecific antibodies'2012 8,133,979'Antibodies against human angiopoietin 2'2012 7,393,936'Method for the recombinant production and purification of protein kinases'2008 6,153,192'Peptides with a characteristic antigenic determinant of .alpha.1-microglobulin'2000 5,994,552'Process for the production of substituted thiazoline-dioxetan substrates and use thereof'1999 5,712,106'Process for the production of substituted thiazolin-dioxetan substrates and use thereof'1998 5,662,911'Benzodiazepine protein conjugates'1997 5,646,255'Immunogens and the use thereof for obtaining antibodies against HBA.sub.1C'1997 5,632,993'Immunogens and the use thereof for obtaining antibodies against HbA.sub.1c'1997 5,595,741'Aminoalkylmaleimides and hapten and antigen derivatives derived therefrom as well as conjugates with peptides or proteins'1997 5,455,357'Substituted thiazoline-dioxetan substrates, process for the production and use'1995 5,304,645'Resorufin derivatives'1994 5,248,620'Non-ionic block copolymers of propylene oxide and ethylene oxide'1993 5,219,764'Hapten-biotin conjugates and their use'1993 5,171,679'Cyanocobalamin acid hydrazides and their conjugates'1992 5,116,762'Method for determining the concentration of fructosamine using a standard solution and method of calibrating the standard solution'1992 5,070,025'Process for the determination of a protein according to fluorescence polarization immunoassay principle'1991 5,032,518'Hapten-protein conjugates and the use therof'1991 5,001,049'Method for determination of HIV specific antibodies'1991 4,990,443'Hapten-protein conjugates and methods of use in immunoassays'1991 4,954,630'Resorufin derivatives'1990 4,925,945'Certain -N-(amino benzoyl)-N\'-(pyridyldithioalkanoyl)-hydrazines and derivatives thereof'1990 4,737,466'N-acyldihydroresorufin derivatives, processes for their preparation, reagents containing them and the use thereof for determining hydrogen peroxide, peroxidate-acting compounds or peroxidase'1988

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1988–2000Patents assigned to BOEHRINGER MANNHEIM GMBH (19)· patent assignee history

1988–2018Based in Weilheim, DE· patent location history

2008–2020Patents assigned to HOFFMANN LA ROCHE (40)· patent assignee history

2008–2018Based in Iffeldorf, DE· patent location history

2012–2018Patents assigned to KLEIN CHRISTIAN (24)· patent assignee history

2012–2018Patents assigned to REGULA JOERG THOMAS (11)· patent assignee history

2014–2020Based in Bonstetten, CH· patent location history

2015–2020Patents assigned to ROCHE GLYCART AG (23)· patent assignee history

2016Based in Heidelberg, DE· patent location history

2019–2020Based in Schlieren, CH· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
HOFFMANN LA ROCHE	40	2008–2020
KLEIN CHRISTIANself	24	2012–2018
ROCHE GLYCART AG	23	2015–2020
BOEHRINGER MANNHEIM GMBH	19	1988–2000
REGULA JOERG THOMAS	11	2012–2018

Locations

Location	Patents	Span
Bonstetten, CH	48	2014–2020
Weilheim, DE	20	1988–2018
Iffeldorf, DE	16	2008–2018
Schlieren, CH	3	2019–2020
Heidelberg, DE	1	2016